Europe PMCopen access
Twelve-Month Real-World Outcomes of Tezepelumab in Severe Asthma: Clinical Remission, Biomarker Changes, and Trigger Burden-A SANI Multicenter Cohort
Severe asthma, Biologics, Thymic Stromal Lymphopoietin, Clinical Remission, Type 2 Inflammation, Real-world Evidence
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 314746
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.